Completed
PHASE2
INTERVENTIONAL
NCT01395940
A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
Interventions
Name:
KLH-2109
Type:
DRUG
Description:
Name:
KLH-2109
Type:
DRUG
Description:
Primary Outcomes
Measure:
The severity score of the pelvic pain
TimeFrame:
8 weeks
Description:
Trial Information
NCT ID
NCT01395940
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Kissei Pharmaceutical Co., Ltd.
Last Updated
December 15, 2025